NASDAQ:PAVM
PAVmed Inc Stock News
$2.25
+0.0500 (+2.27%)
At Close: May 09, 2024
PAVmed: A True Game-Changer For Medical Device Innovation
04:48pm, Monday, 14'th Jun 2021
PAVmed's main commercial-stage product, EsoCheck/EsoGuard, is a life-saving product addressing a $25bil market and is supported by Exact Sciences founder Stanley Lapidus.
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2021 Results - Earnings Call Transcript
10:45pm, Monday, 17'th May 2021
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2021 Results - Earnings Call Transcript
PAVmed to Hold Business Update Conference Call on May 17, 2021
09:30am, Monday, 03'rd May 2021
Company conference call and webcast at 4:30 PM EDT
PAVmed to Present at the 20th Annual Needham Healthcare Conference
09:30am, Thursday, 08'th Apr 2021
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company,
PAVmed's (PAVM) CEO Lishan Aklog on Business Update and Preliminary Q4 2020 Results - Earnings Call Transcript
03:13pm, Monday, 22'nd Feb 2021
PAVmed's (PAVM) CEO Lishan Aklog on Business Update and Preliminary Q4 2020 Results - Earnings Call Transcript
PAVmed's Esophageal Diagnostic Tools Should Create Strong Shareholder Value
03:55pm, Tuesday, 09'th Feb 2021
PAVmed has a suite of medical devices that could improve on the current standard of care in multiple areas. Based on the opportunity in esophageal cancer screening alone, the company looks substantial
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
12:04pm, Tuesday, 22'nd Dec 2020
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda
PAVmed Announces Registered Direct Offering of its Common Stock
09:29am, Friday, 11'th Dec 2020
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda
PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript
09:22pm, Tuesday, 17'th Nov 2020
PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript
PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update
04:00pm, Tuesday, 17'th Nov 2020
Conference call to be held today at 4:30 p.m. Eastern time
PAVmed to Hold Business Update Conference Call on November 17, 2020
09:30am, Monday, 02'nd Nov 2020
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda
There Is Progress At PAVmed, But More Patience Is Required
07:58am, Friday, 30'th Oct 2020
The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage. Yet, like for most pre-revenue medical d
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call Transcript
09:52pm, Tuesday, 18'th Aug 2020
PAVmed Inc. (NASDAQ:PAVM) Q2 2020 Earnings Conference Call August 18, 2020 4:30 P.M.
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
08:14pm, Tuesday, 18'th Aug 2020
Conference call to be held today at 4:30 p.m. Eastern timeNEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, mu
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Catalent Inc (NYSE: CTLT)
CureVac N.V. (NASDAQ: CVAC) (follow-on buying after a 250% advance on its debut Friday...
